• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Glaucoma - Pipeline Review, Q4 2010 - Product Image

Glaucoma - Pipeline Review, Q4 2010

  • ID: 1496195
  • December 2010
  • 69 pages
  • Global Markets Direct

Glaucoma - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Glaucoma Pipeline Review, Q4 2010”, provides an overview of the Glaucoma therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. “Glaucoma-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Glaucoma.
- A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glaucoma Overview
Therapeutics Development
An Overview of Pipeline Products for Glaucoma
Glaucoma Therapeutics under Development by Companies
Glaucoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Glaucoma Therapeutics Development
Alcon, Inc.
Bausch & Lomb Incorporated
Allergan, Inc.
Quark Pharmaceuticals, Inc.
Merck & Co., Inc.
Santen Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Sylentis
Novagali Pharma SA
Novartis AG
Kowa Company, Ltd.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
ISTA Pharmaceuticals, Inc.
OphthalmoPharma Ltd.
Inspire Pharmaceuticals, Inc.
InSite Vision Incorporated
Proneuron Biotechnologies, Inc.
Can-Fite BioPharma Ltd.
Lpath, Inc.
Biovitrum AB
ACADIA Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Resverlogix Corp.
Sirion Therapeutics, Inc.
Summit Corporation plc
Ceregene, Inc.
AC Immune SA
Domain Therapeutics
LABORATOIRES THEA
Senju Pharmaceutical Co., Ltd.
Gene Signal International SA.
Surface Logix, Inc.
Inotek Pharmaceuticals Corporation
CeNeRx BioPharma, Inc.
Transtech Pharma, Inc.
Aerie Pharmaceuticals, Inc.
SIFI Pharma
Universities/Institutes Involved in Glaucoma Therapeutics Development
Glaucoma Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Bimatoprost + Brimonidine Tartrate + Timolol maleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DuoTrav - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Saflutan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNJ-2022 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T2345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorometholone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketorolac Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moxaverine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Subconjunctival Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Glaucoma - Featured News
Sep 09, 2010: iSONEP Phase I Results Highlighted at Three Major Scientific Meetings
Sep 07, 2010: Promedior Initiates Phase IIa Clinical Study Of PRM-151 In Prevention Of Post-Surgical Scarring In Glaucoma Patients
Sep 06, 2010: Sylentis Receives Authorization To Commence Phase I/II Clinical Trial With SYL040012 For Treating Elevated Intraocular Pressure And Glaucoma
Jul 22, 2010: R-Tech Ueno Reports Change In Storage Condition For Rescula Eye Drops 0.12%
Jul 06, 2010: Sylentis Completes Phase I trial With SYL040012 To Treat Elevated Intraocular Pressure And Glaucoma
Jun 28, 2010: Quark's QPI-1007 Exhibits Neuroprotective Effects In Glaucoma Model
Jun 17, 2010: Inotek Initiates Multiple-Dose Phase II Clinical Trial Of INO-8875 In Patients With Glaucoma
May 24, 2010: Can-Fite Receives Israeli MoH Approval To Conduct Phase II Clinical Trial With CF101 In Glaucoma Patients
May 06, 2010: Santen Launches TAFLOTAN In Korea For Treatment Of Glaucoma And Ocular Hypertension
May 04, 2010: Inotek Pharmaceuticals Presents Preclinical Data At ARVO Confirming That INO-8875 Lowers IOP By Increasing Outflow through The Trabecular Meshwork
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos